People with mild cognitive impairment due to Alzheimer's can now start Leqembi with weekly shots at home. Leqembi Iqlik (lecanemab-irmb) is an under-the-skin form approved as a day-one dose for early Alzheimer's disease. Early Alzheimer's means mild memory trouble due to Alzheimer's or mild dementia. For people at that stage, home treatment removes the need for regular infusion visits to start.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What is the new starting dose?
- Who can consider it?
- Does home dosing change safety checks?
- How does treatment fit daily life?
What is the new starting dose?
Eisai U.S. said the FDA approved Leqembi Iqlik as an initiation dose on July 13, 2026, according to the FDA approval notice. The starting dose is 500 mg once a week as two 250-mg autoinjector injections.
Each shot takes about 15 seconds and can be given at home. Eisai said the initiation product would move through U.S. specialty pharmacies for late-August launch. Ask your clinic where it orders the drug and how training works.
Who can consider it?
Eisai and Biogen state the drug is only for adults with mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia, according to the company announcement. Those two stages together make up early Alzheimer's.
Treatment generally requires a test that confirms amyloid in the brain. Talk through these checks with your doctor: If another cause explains the memory changes, this drug is not a fit. Bring a medication list and a family member to that visit.
- adult with mild cognitive impairment thought to be due to Alzheimer's, or mild Alzheimer's dementia
- test confirms amyloid buildup in the brain
- care team can arrange MRIs and follow-up visits
Does home dosing change safety checks?
Home dosing does not lower the need for brain MRI scans for ARIA, according to context from NeurologyLive and the Alzheimer's Drug Discovery Foundation in their treatment explainer. ARIA means swelling or bleeding in the brain linked to amyloid treatment. Scans can catch changes before you feel them.
Counseling before and during treatment remains important. People with two copies of the APOE4 gene face higher risk and need a clear plan for risks and benefits. Keep every MRI, report new symptoms fast, and confirm who to call after hours.
How does treatment fit daily life?
The Alzheimer's Association notes that a day-one home shot cuts infusion-center visits, travel, and disruption for patients and caregivers in its approval statement. That can make starting and staying on treatment more workable. Families still need a steady weekly routine and safe storage.
Eisai U.S. says patients can stay on the under-the-skin form from start through ongoing care and can switch between IV and shot forms when needed. After 18 months of starting treatment, the company states patients may move to 360-mg weekly shots for maintenance. Ask the clinic to map the full 18-month plan before the first dose.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: What People With Mild Cognitive Impairment Should Know About the News
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: What People With Mild Cognitive Impairment Should Know About the News
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: What People With Mild Cognitive Impairment Should Know About the News
